Previous 10 | Next 10 |
The following slide deck was published by Atea Pharmaceuticals, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Atea Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call Presentation
Atea Pharmaceuticals press release (NASDAQ:AVIR): Q1 GAAP EPS of -$0.51 beats by $0.05. Cash and Cash Equivalents: $705.5 million at March 31, 2022 compared to $764.4 million at December 31, 2021 For further details see: Atea Pharmaceuticals GAAP EPS of -$0.51 beats by $0.05
New clinical results from MORNINGSKY trial shows 71% reduction in hospitalization (secondary endpoint) in broad patient population with COVID-19 treated with bemnifosbuvir (AT-527) versus placebo (p=0.047, unadjusted, exploratory) New clinical results from final analysis of Phase ...
BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Tuesday, May 10, 2022, at 8:00 a.m. ET to report financial res...
Shares of Atea Pharmaceuticals Inc. (NASDAQ:AVIR) traded today at $93.80, eclipsing its 52-week high. This new high was reached on above average trading volume as 62.4 million shares traded hands, while the average 30-day volume is approximately 993,000 shares. Atea Pharmaceuticals Inc i...
Shares of Atea Pharmaceuticals Inc. (NASDAQ:AVIR) traded today at $93.80, eclipsing its 52-week high. This new high was reached on above average trading volume as 62.3 million shares traded hands, while the average 30-day volume is approximately 1 million shares. Atea Pharmaceuticals Inc...
BOSTON, March 28, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today presented two posters highlighting nonclinical data demonstrating the nonclinical safety of bemnifosbuvir (AT-527) at the Society of...
Gainers: Incannex Healthcare Limited (NASDAQ:IXHL) +271%. Esperion Therapeutics (NASDAQ:ESPR) +10%. GitLab (NASDAQ:GTLB) +9%. Niu Technologies (NASDAQ:NIU) +7%. Lordstown Motors (NASDAQ:RIDE) +6%. Losers: Coupa Software Incorporated (NASDAQ:COUP) -29%. AnaptysB...
Atea Pharmaceuticals, Inc. (AVIR) Q4 2021 Earnings Conference Call February 28, 2022, 04:30 PM ET Company Participants Jonae Barnes - SVP, IR and Corporate Communications Jean-Pierre Sommadossi - Founder and CEO Janet Hammond - Chief Development Officer Andrea Corcoran - CFO and EVP, Legal Jo...
Image source: The Motley Fool. Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) Q4 2021 Earnings Call Feb 28, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Atea Pharmaceuticals, Inc. (AVIR) Q4 2021 Earnings Call Transcri...
News, Short Squeeze, Breakout and More Instantly...
Atea Pharmaceuticals Inc. Company Name:
AVIR Stock Symbol:
NASDAQ Market:
Atea Pharmaceuticals Inc. Website:
97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study EASL Presentations Continue to Support Best-in-Class Potential with High Antiviral Potency, Short Treatment Duration, Low Risk of Drug Interaction and High Barr...
Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A Resistance-Associated Substitutions (RAS) Detected in HCV-infected Patients BOSTON, May 22, 20...
Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H’24 Global Phase 2 HCV Study On Track to Report Complete SVR12 Results 2H’24 Multiple Presentations Showcasing Preclinical and New Phase 2 Efficacy Data to ...